Trulieve Receives DEA Registrations for State-Licensed Medical Marijuana Operations

The registrations fall under a federal framework that maintains controls under the Controlled Substances Act.

Rhea-AI Summary

Trulieve Cannabis (TRLV) has received DEA registrations for medical marijuana dispensaries as part of the agency's initial issuance to qualifying state-licensed operators.

The registrations mark the first phase of an April Attorney General order establishing a federal framework for qualifying medical marijuana businesses while maintaining controls under the Controlled Substances Act. Trulieve applied in April following the rescheduling of state-licensed medical marijuana to Schedule III. The company said federal reclassification opens the door for clinical research.

1 point · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointTrulieve received DEA registrations for medical marijuana dispensaries in the initial issuance to qualifying state-licensed operators.

Negative

• None.

Argus 15 min delay 19 alerts

+5.64% vs previous close $10.86 last price 2.7x rel. volume Open Argus

Details

Market Reaction – TRLV

$10.34 – $10.94 Day Range

$2.09B Mkt Cap at Last Price

On Nov 2, the day this news came out, the latest delayed price for TRLV is 5.64% above the previous close. Our momentum scanner has recorded 19 alerts for this stock so far that day. The latest delayed price is $10.86. Relative volume is elevated at 2.7x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

schedule iii

1 terms

schedule iii regulatory

"rescheduling of state-licensed medical marijuana to Schedule III"

A Schedule III classification is a regulatory category for drugs and substances that have a recognized medical use but a moderate risk of dependence or abuse, placing them between higher-risk controlled drugs and over-the-counter medicines. For investors, this matters because it shapes how a product can be manufactured, prescribed, marketed and distributed — affecting potential sales, regulatory hurdles, labeling requirements and legal exposure in the market; think of it as a middle level of control that influences commercial access and compliance costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TALLAHASSEE, Fla., Nov. 2, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that Trulieve has received registrations for medical marijuana dispensaries as part of the initial registrations issued by the U.S. Drug Enforcement Administration (DEA). On Friday, the DEA announced it has begun the initial issuance of federal registrations to qualifying state licensed medical marijuana dispensaries, marking the first phase of the Attorney General's order in April that established a federal framework for qualifying medical marijuana businesses while maintaining federal controls under the Controlled Substances Act. In April, Trulieve applied for DEA registration for its state-licensed operations following the rescheduling of state-licensed medical marijuana to Schedule III under the Controlled Substances Act.

"Today marks another historic milestone for patients, physicians, and Trulieve, made possible by the bold action taken by the Trump Administration on common sense cannabis reform," said Trulieve Chief Executive Officer Kim Rivers. "Federal reclassification of state licensed medical marijuana opens the door for clinical research while creating a level playing field for responsible operators like Trulieve. We appreciate the DEA's work to advance this historic change and its continued engagement with state-licensed medical cannabis operators as the new federal framework is implemented."

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com.

Facebook: @Trulieve   
Instagram: @Trulieve
X: @Trulieve

Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-receives-dea-registrations-for-state-licensed-medical-marijuana-operations-302926512.html

SOURCE Trulieve Cannabis Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What DEA registrations did Trulieve receive?

Trulieve received DEA registrations for medical marijuana dispensaries as part of the agency's initial issuance to qualifying state-licensed operators. The issuance is the first phase of the federal framework established by the Attorney General's April order.